Gilead Sciences’ antiviral demonstrated 100% efficacy for HIV prevention in cisgender women in Phase III trial results.The twice-yearly lenacapavir shot proved superior to Gilead’s already-approved oral medicines for HIV prevention, Truvada and Descovy.
In the PURPOSE 1 trial, zero cases of HIV infection occurred among 2,134 women in the lenacapavir group, compared to 16 cases in the 1,068 women in the Truvada arm and 39 incidents among 2,136 women treated with Descovy. The long-acting shot was well-tolerated with no significant safety concerns, according to Gilead.